





Methylation profiling report

Supplier information

Sample identifier: sampleName1540660609 **Automatic prediction** Sentrix ID: 202273260096_R03C01 Array type: **EPIC KRYO DNA** Material type: **KRYO DNA** Material type: Gender: Gender: female NA Supplier diagnosis: Legend: ✓ OK Supplier information or Warning, missmatch of prediction prediction not available and supplier information


Brain tumor methylation classifier results (v11b4)

Methylation classes (MCs with score >= 0.3)		Calibrated score	Interpretation	
methylation class glioblastoma, IDH wildtype, H3.3 G34 mutant		0.98	match	~
Legend: ✓ Match (score >= 0.9) X No match (score < 0.9): possibly still relevant for low tumor content and low DNA Match to MC family member (score >= 0.5)				

Class descriptions

Methylation class glioblastoma, IDH wildtype, H3.3 G34 mutant: The methylation class "glioblastoma, IDH wildtype, H3.3 G34 mutant" almost exclusively comprises tumors with glioblastoma, IDH wildtype histology as well as rare cases with anaplastic astrocytoma, IDH wildtype or embryonal histology. Location is typically in the supratentorial hemispheres; Median age is 19.5 years (range 0 to 40). The vast majority of cases in this class harbor mutations of codon 34 of the H3.3 gene (H3F3A). Copy number changes are numerous, with gain of 1q and 7 (>40% of cases) and (focal) loss of 4q, 10q and 13 (each in over 40%) being most frequent

Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment. (see Hovestadt & Zapatka, http://www.bioconductor.org/packages/devel/bioc/html/conumee.html)

MGMT promotor methylation (MGMT-STP27)

MGMT promotor status prediction



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

Disclaimer

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

Run information

Report: idat_reportBrain_v11b4_sample Version 2.0 Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0
idat_reportBrain_v11b4	2.0